Antiaging Quantum Living Inc.
0.9900+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · AAQL · USD
Key Stats
Market Cap
29.70MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Antiaging Quantum Living posted Q2 FY2026 revenue of $291K, up 44% y/y from $202K, driven entirely by technical operation support and maintenance services, while gross margin slipped to 80.5% from 99.9% on higher costs. Operating loss narrowed to $138K from $214K y/y, thanks to 10% lower expenses like wages and fees, yielding a net loss of $133K versus $214K last year; diluted EPS improved to $(0.0045) across 30M shares. Cash climbed to $406K on $220K related-party funding, though operations burned $185K and long-term related-party debt sits at $1.7M, non-interest-bearing through 2029. No non-GAAP metrics disclosed in the 10-Q. Reliance on one customer spells trouble.
10-K
FY2025 results
Antiaging Quantum Living Inc. posted FY2025 revenue of $817,898, up 10,806.8% y/y from $7,499, driven entirely by new online platform technical support and maintenance services while prior health product sales and advertising vanished. Gross profit hit $428,517 at 52.4% margin, but operating expenses tripled to $1,218,476 on expansion costs like rentals and wages, yielding an operating loss of $789,959 and net loss of $720,409, or $(0.0240) per diluted share on 29,995,000 shares. Q4 momentum faltered amid heavy startup outlays, though cash swelled to $370,549 via $1.17M in related-party financing, with $1.28M debt converted to long-term notes. No quarterly breakdowns disclosed. Dependence on one customer risks revenue cliff.
10-Q
Q3 FY2025 results
Antiaging Quantum Living Inc. ramped up revenue to $154K in Q3 FY2025 ended December 31, 2024, a sharp 2352% y/y jump from $6K, driven by new technical support services while costs held at 3.3% of sales for a solid gross margin. Yet operating expenses ballooned to $348K from $103K y/y, fueled by rentals and wages for expansion, yielding an operating loss of $199K versus $97K last year; net loss widened to $129K after a $70K renovation subsidy offset some pain. For the nine months, revenue hit $530K (6964% y/y growth) against a $541K net loss, with EPS at $(0.018) aligning to 30M diluted shares. Cash climbed to $202K, backed by $1.7M in non-interest-bearing notes due 2029 from related parties and third parties, while FCF isn't disclosed in the 10-Q. Revenue now flows from Asia-Pacific platforms. Competition in health tech markets poses ongoing pressure.
10-Q
Q2 FY2025 results
Antiaging Quantum Living ramped up revenue to $173K in Q2 FY2025 ended September 30, 2024, a leap from zero last year, driven by $124K in health and beauty product sales and $252K YTD from technical support services—yet operating expenses surged 1,363% y/y to $357K on rentals, wages, and startup costs like cloud hosting. This fueled a $198K operating loss, widening 711% y/y, with net loss matching at $198K since no taxes hit; EPS fell to $(0.0066) on 30M shares. Cash dwindled to $37K after $223K operating outflow, offset by $139K related-party advances, while $431K third-party debt matures in 2026 interest-free. Shareholders' deficit deepened to $842K. Still, revenue momentum hints at traction. Competition in e-commerce platforms poses a key risk.
10-Q
Q1 FY2025 results
Antiaging Quantum Living Inc. posted revenue of $202,069 for Q1 FY2025 ended June 30, 2024, up sharply from $1,200 a year earlier, driven by new sales of health and beauty products via its mobile app, while costs stayed negligible at $165. Yet operating expenses ballooned to $415,837 from $30,927, fueled by rental costs, employee wages, and startup outlays for business expansion in China, yielding an operating loss of $213,933 versus $29,727 last year. Net loss hit $213,908, or $0.0071 per diluted share on 29,955,000 shares, matching the operating figure with no material other items. Cash dipped to $122,651 from $166,552, with free cash flow negative at $(244,450) (derived) after $29,643 in fixed asset buys; related-party advances of $810,917 and $416,570 in non-interest-bearing third-party debt due 2026 cover liquidity, though working capital remains negative at $767,839. Revenue growth signals early traction. Internal controls show material weaknesses in GAAP knowledge and segregation of duties.
ARQQ
Arqit Quantum Inc.
45.37+2.38
CHWY
Chewy, Inc.
33.58-0.58
DIBS
1stdibs.com, Inc.
3.89+0.07
MDCE
Medical Care Technologies Inc.
0.00+0.00
PDD
PDD Holdings Inc.
138.08+0.05
PTRN
Pattern Group Inc. - Series A
16.91+0.05
QS
QuantumScape Corporation
15.84+0.25
RERE
ATRenew Inc.
3.82-0.09
WBUY
WEBUY GLOBAL LTD.
2.54-0.01
YJ
Yunji Inc. - American Depositor
1.85-0.01